BNTC
Benitec Biopharma Inc.
Biotechnology
Market Cap$416M
5Y Perf.-90.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BNTC vs QURE
Revenue, margins, valuation, and 5-year total return — side by side.
QURE
uniQure N.V.
Biotechnology
Market Cap$1.49B
5Y Perf.-64.0%
BNTC vs QURE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BNTC | QURE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $416M | $1.49B |
| Revenue (TTM) | $556K | $18M |
| Net Income (TTM) | $-51M | $-209M |
| Gross Margin | -1.2% | 74.1% |
| Operating Margin | -99.9% | -10.8% |
| Total Debt | $849K | $537M |
| Cash & Equiv. | $98M | $80M |
BNTC vs QURE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BNTC
QURE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Benitec Biopharma I… (BNTC) | 100 | 9.8 | -90.2% |
| uniQure N.V. (QURE) | 100 | 36.0 | -64.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BNTC vs QURE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: QURE leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Benitec Biopharma Inc. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
BNTC
Benitec Biopharma Inc.
The Growth Play
BNTC is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- EPS growth 60.8%
- Lower volatility, beta 1.35, Low D/E 0.9%, current ratio 54.67x
- -26.7% ROA vs QURE's -27.2%
Best for: growth exposure and sleep-well-at-night
QURE
uniQure N.V.
The Income Pick
QURE carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.26
- 86.3% 10Y total return vs BNTC's -97.0%
- Beta 1.26, current ratio 10.43x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | QURE | -40.6% revenue growth vs BNTC's -141.6% |
| Quality / Margins | QURE | -11.5% margin vs BNTC's -91.5% |
| Stability / Safety | QURE | Beta 1.26 vs BNTC's 1.35 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | QURE | +140.1% vs BNTC's -10.3% |
| Efficiency (ROA) | BNTC | -26.7% ROA vs QURE's -27.2% |
BNTC vs QURE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
FY 2025
BNTC vs QURE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBNTCLAGGINGQURE
QUREuniQure N.V.
2leads
BNTCBenitec Biopharma Inc.
2leads
6 Total Categories
CATEGORYLEADERvs QUREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
QURE4/5
Valuation MetricsMultiples, price ratios, and targets
BNTC2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BNTC5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
QURE4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
QURE leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
QURE is the larger business by revenue, generating $18M annually — 32.5x BNTC's $556,000. QURE is the more profitable business, keeping -11.5% of every revenue dollar as net income compared to BNTC's -91.5%.
| Metric | BNTCBenitec Biopharma… | QUREuniQure N.V. |
|---|---|---|
| RevenueTrailing 12 months | $556,000 | $18M |
| EBITDAEarnings before interest/tax | -$56M | -$183M |
| Net IncomeAfter-tax profit | -$51M | -$209M |
| Free Cash FlowCash after capex | -$19M | -$172M |
| Gross MarginGross profit ÷ Revenue | -1.2% | +74.1% |
| Operating MarginEBIT ÷ Revenue | -99.9% | -10.8% |
| Net MarginNet income ÷ Revenue | -91.5% | -11.5% |
| FCF MarginFCF ÷ Revenue | -33.7% | -9.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +127.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +21.2% | -3.7% |
QURE leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
BNTC leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | BNTCBenitec Biopharma… | QUREuniQure N.V. |
|---|---|---|
| Market CapShares × price | $416M | $1.5B |
| Enterprise ValueMkt cap + debt − cash | $319M | $1.9B |
| Trailing P/EPrice ÷ TTM EPS | -11.56x | -6.98x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 92.42x |
| Price / BookPrice ÷ Book value/share | 4.52x | 6.98x |
| Price / FCFMarket cap ÷ FCF | — | — |
BNTC leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
BNTC leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
BNTC delivers a -27.2% return on equity — every $100 of shareholder capital generates $-27 in annual profit, vs $-146 for QURE. BNTC carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to QURE's 2.70x. On the Piotroski fundamental quality scale (0–9), QURE scores 4/9 vs BNTC's 3/9, reflecting mixed financial health.
| Metric | BNTCBenitec Biopharma… | QUREuniQure N.V. |
|---|---|---|
| ROE (TTM)Return on equity | -27.2% | -145.8% |
| ROA (TTM)Return on assets | -26.7% | -27.2% |
| ROICReturn on invested capital | — | -50.7% |
| ROCEReturn on capital employed | -57.6% | -29.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 2.70x |
| Net DebtTotal debt minus cash | -$97M | $456M |
| Cash & Equiv.Liquid assets | $98M | $80M |
| Total DebtShort + long-term debt | $849,000 | $537M |
| Interest CoverageEBIT ÷ Interest expense | — | -2.92x |
BNTC leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
QURE leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in QURE five years ago would be worth $7,419 today (with dividends reinvested), compared to $1,692 for BNTC. Over the past 12 months, QURE leads with a +140.1% total return vs BNTC's -10.3%. The 3-year compound annual growth rate (CAGR) favors BNTC at 48.1% vs QURE's 3.8% — a key indicator of consistent wealth creation.
| Metric | BNTCBenitec Biopharma… | QUREuniQure N.V. |
|---|---|---|
| YTD ReturnYear-to-date | -3.5% | +3.2% |
| 1-Year ReturnPast 12 months | -10.3% | +140.1% |
| 3-Year ReturnCumulative with dividends | +224.6% | +11.7% |
| 5-Year ReturnCumulative with dividends | -83.1% | -25.8% |
| 10-Year ReturnCumulative with dividends | -97.0% | +86.3% |
| CAGR (3Y)Annualised 3-year return | +48.1% | +3.8% |
QURE leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BNTC and QURE each lead in 1 of 2 comparable metrics.
Risk & Volatility
QURE is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than BNTC's 1.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BNTC currently trades 70.8% from its 52-week high vs QURE's 33.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BNTCBenitec Biopharma… | QUREuniQure N.V. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.35x | 1.26x |
| 52-Week HighHighest price in past year | $17.15 | $71.50 |
| 52-Week LowLowest price in past year | $9.93 | $8.73 |
| % of 52W HighCurrent price vs 52-week peak | +70.8% | +33.8% |
| RSI (14)Momentum oscillator 0–100 | 55.1 | 68.0 |
| Avg Volume (50D)Average daily shares traded | 144K | 3.3M |
Evenly matched — BNTC and QURE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BNTC as "Buy" and QURE as "Buy". Consensus price targets imply 122.4% upside for BNTC (target: $27) vs 49.5% for QURE (target: $36).
| Metric | BNTCBenitec Biopharma… | QUREuniQure N.V. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $27.00 | $36.11 |
| # AnalystsCovering analysts | 7 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
QURE leads in 2 of 6 categories (Income & Cash Flow, Total Returns). BNTC leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
Best OverallBenitec Biopharma Inc. (BNTC)Leads 2 of 6 categories
Loading custom metrics...
BNTC vs QURE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BNTC or QURE a better buy right now?
Analysts rate Benitec Biopharma Inc.
(BNTC) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BNTC or QURE?
Over the past 5 years, uniQure N.
V. (QURE) delivered a total return of -25. 8%, compared to -83. 1% for Benitec Biopharma Inc. (BNTC). Over 10 years, the gap is even starker: QURE returned +86. 3% versus BNTC's -97. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BNTC or QURE?
By beta (market sensitivity over 5 years), uniQure N.
V. (QURE) is the lower-risk stock at 1. 26β versus Benitec Biopharma Inc. 's 1. 35β — meaning BNTC is approximately 7% more volatile than QURE relative to the S&P 500. On balance sheet safety, Benitec Biopharma Inc. (BNTC) carries a lower debt/equity ratio of 1% versus 3% for uniQure N. V. — giving it more financial flexibility in a downturn.
04Which is growing faster — BNTC or QURE?
On earnings-per-share growth, the picture is similar: Benitec Biopharma Inc.
grew EPS 60. 8% year-over-year, compared to 29. 7% for uniQure N. V.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BNTC or QURE?
uniQure N.
V. (QURE) is the more profitable company, earning -1236. 0% net margin versus -91. 5% for Benitec Biopharma Inc. — meaning it keeps -1236. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QURE leads at -1166. 8% versus -99. 9% for BNTC. At the gross margin level — before operating expenses — QURE leads at 89. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BNTC or QURE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BNTC or QURE better for a retirement portfolio?
For long-horizon retirement investors, uniQure N.
V. (QURE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Both have compounded well over 10 years (QURE: +86. 3%, BNTC: -97. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BNTC and QURE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.